News

Ali Beckman, MS, RD, LD, CEDS-C, talks about psychiatry and how the role of nutrition.

A roundup of psychiatric news from around the globe for the week of March 30, 2025.

Frank A. Clark, MD, discusses his new "Psyched Perspectives" series on Psychiatric Times.

Eisenhower Fellowships has launched its 2022 USA Justice Program with an inaugural cohort of 11 mid-career US professionals from a variety of fields, including psychiatry, to address issues in inequality.

One psychiatrist considers the advantages of virtual psychiatric treatment for both patients and clinicians.

Real true, posttraumatic stress disorder [PTSD] is going to have an impact, certainly on the next generation and maybe generations after that," said Rachel Yehuda, PhD.

Adhansia XR, also known as methylphenidate hydrochloride, was given approval by the FDA for the treatment of ADHD. However, this approval has been met with some controversy.

In its third Phase III study, SPN-812 met its primary endpoint with positive results. Marking a major step for Supernus Pharmaceuticals novel ADHD treatment.<br />

In today's world, so many people have mobile smartphones that mHealth apps seem a natural next step of healthcare. But until now, there hasn't been a study examining the efficacy of mHealth apps for the treatment of depression.

A recent study from Johns Hopkins Medicine and Sheppard Pratt Health Systems shows a suprising connection between Schizophrenia and the Epstein-Barr Virus, aka mono.

17 million people in the United States live with ADHD and not only is treatment essential, a new study shows that living without treatment will reduce life expectancy for patients.

The FDA published a final order requiring manufactures to file for a PMA for most uses of ECT devices. This order also reclassified ECT devices used in the treatment of catatonia or severe major depressive episodes.

Depression screening is important in primary care, but according to new findings screening for depression is less common in men and minorities.

After a priority review granted in May, brexanolone has been proven to be a potentially rapid and durable treatment of post-partum depression (PPD) in new mothers.

A recent meta analysis of the relationship between tardive dyskinesia and common antipsychotic medications re-established findings that 2nd-generation antipsychotics have a reduced risk of Tardive Dyskinesia.